Company news

Immutep Ltd news in 2025

Immutep Ltd's news releases, calls and decks from 2025, newest first.

View company

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

December 22, 2025

Positive Update on IMP761 Phase 1

December 21, 2025

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

December 16, 2025

TACTI-004 phase III trial enrolment continues at robust pace

December 15, 2025

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

December 8, 2025

Immutep enters into Strategic Collaboration with Dr. Reddy's

December 8, 2025

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

December 2, 2025

New data presentation from AIPAC-003 Phase II for SABCS

December 1, 2025

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

November 13, 2025

EFTISARC-NEO Phase II results presented at CTOS 2025

November 12, 2025

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

November 3, 2025

Immutep Receives A$4.6 million French R&D Tax Incentive

November 2, 2025

Immutep Quarterly Activities Report Q1 FY26

October 29, 2025

Primary Endpoint Met in STS Trial - presented at ESMO 2025

October 19, 2025

Improved ORR in First Line NSCLC - presented at ESMO 2025

October 19, 2025

Immutep Announces Successful Completion of FDA Project Optimus Requirements

October 13, 2025

Successful Completion of FDA Project Optimus Requirements

October 12, 2025

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

October 9, 2025

TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC

October 8, 2025

Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti

September 22, 2025

New investigator-initiated Phase II trial for Efti

September 21, 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

September 8, 2025

Appendix 4E & 2025 Full Year Statutory Accounts

August 28, 2025

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

August 5, 2025

FDA feedback received for head & neck cancer in CPS below 1

August 4, 2025

Immutep Quarterly Activities Report Q4 FY25

July 30, 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

July 29, 2025

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

July 28, 2025

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

June 23, 2025

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025

Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial

May 25, 2025

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 15, 2025

High Response Rates achieved in Lung Cancer in INSIGHT-003

May 14, 2025

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

May 5, 2025

Excellent Overall Survival in Head & Neck Cancer Patients

May 4, 2025

Immutep Quarterly Activities Report Q3 FY25

April 29, 2025

Immutep to Participate in Upcoming Investor Conferences

April 2, 2025

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

March 25, 2025

First patient dosed in phase 3 TACTI-004 lung cancer trial

March 24, 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

March 20, 2025

Decks in 2025